RU2014121260A - Фармацевтические композиции - Google Patents
Фармацевтические композиции Download PDFInfo
- Publication number
- RU2014121260A RU2014121260A RU2014121260/15A RU2014121260A RU2014121260A RU 2014121260 A RU2014121260 A RU 2014121260A RU 2014121260/15 A RU2014121260/15 A RU 2014121260/15A RU 2014121260 A RU2014121260 A RU 2014121260A RU 2014121260 A RU2014121260 A RU 2014121260A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- diabetes mellitus
- diabetes
- hydrate
- insulin receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Фармацевтическая композиция для предупреждения или лечения сахарного диабета, заболеваний, связанных с сахарным диабетом или осложнений сахарного диабета, включающая(А) (1S)-1,5-ангидро-1-[5-(4-этоксибензил)-2-метокси-4-метилфенил]-1-тио-D-глюцитол или его фармацевтически приемлемую соль или гидрат или соль гидрата, и(B) по меньшей мере, одно средство из группы, состоящей из усилителей чувствительности рецепторов к инсулину, инсулинов, ингибиторов дипептидилпептидазы IV, ингибиторов α-глюкозидазы и миметиков GLP-1.2. Фармацевтическая композиция по п. 1, где (В) представляет собой усилитель чувствительности рецепторов к инсулину.3. Фармацевтическая композиция по п. 2, в которой усилитель чувствительности рецепторов к инсулину представляет собой пиоглитазон.4. Фармацевтическая композиция по п. 1, в которой ингибитор дипептидилпептидазы IV представляет собой ситаглиптин или вилдаглиптин.5. Фармацевтическая композиция по п. 1, в которой ингибитор α-глюкозидазы представляет собой воглибозу, миглитол или акарбозу.6. КомбинацияА) (1S)-1,5-ангидро-1-[5-(4-этоксибензил)-2-метокси-4-метилфенил]-1-тио-D-глюцитола или его фармацевтически приемлемой соли или гидрата или соли гидрата, и(B) по меньшей мере, одного средства из группы, состоящейиз усилителей чувствительности рецепторов к инсулину, инсулинов, ингибиторов дипептидилпептидазы IV, ингибиторов α-глюкозидазы и миметиков GLP-1 для применения в способе предупреждения или лечения сахарного диабета, заболеваний, связанных с сахарным диабетом или осложнений сахарного диабета, где (А) и (В) вводят нуждающемуся в этом пациенту одновременно или раздельно.7. Комбинация по п. 6, где (В) представляет собо�
Claims (10)
1. Фармацевтическая композиция для предупреждения или лечения сахарного диабета, заболеваний, связанных с сахарным диабетом или осложнений сахарного диабета, включающая
(А) (1S)-1,5-ангидро-1-[5-(4-этоксибензил)-2-метокси-4-метилфенил]-1-тио-D-глюцитол или его фармацевтически приемлемую соль или гидрат или соль гидрата, и
(B) по меньшей мере, одно средство из группы, состоящей из усилителей чувствительности рецепторов к инсулину, инсулинов, ингибиторов дипептидилпептидазы IV, ингибиторов α-глюкозидазы и миметиков GLP-1.
2. Фармацевтическая композиция по п. 1, где (В) представляет собой усилитель чувствительности рецепторов к инсулину.
3. Фармацевтическая композиция по п. 2, в которой усилитель чувствительности рецепторов к инсулину представляет собой пиоглитазон.
4. Фармацевтическая композиция по п. 1, в которой ингибитор дипептидилпептидазы IV представляет собой ситаглиптин или вилдаглиптин.
5. Фармацевтическая композиция по п. 1, в которой ингибитор α-глюкозидазы представляет собой воглибозу, миглитол или акарбозу.
6. Комбинация
А) (1S)-1,5-ангидро-1-[5-(4-этоксибензил)-2-метокси-4-метилфенил]-1-тио-D-глюцитола или его фармацевтически приемлемой соли или гидрата или соли гидрата, и
(B) по меньшей мере, одного средства из группы, состоящей
из усилителей чувствительности рецепторов к инсулину, инсулинов, ингибиторов дипептидилпептидазы IV, ингибиторов α-глюкозидазы и миметиков GLP-1 для применения в способе предупреждения или лечения сахарного диабета, заболеваний, связанных с сахарным диабетом или осложнений сахарного диабета, где (А) и (В) вводят нуждающемуся в этом пациенту одновременно или раздельно.
7. Комбинация по п. 6, где (В) представляет собой усилитель чувствительности рецепторов к инсулину.
8. Комбинация по п. 6, где сахарный диабет является диабетом 2 типа.
9. Комбинация по п. 7, где сахарный диабет является диабетом 2 типа.
10. Комбинация по любому из пп. 6-9, где осложнением сахарного диабета является диабетическая ретинопатия, диабетическая невропатия, цереброваскулярное расстройство, ишемическая болезнь сердца или болезнь периферических артерий.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009100210 | 2009-04-16 | ||
| JP2009-100210 | 2009-04-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011146335/15A Division RU2532330C2 (ru) | 2009-04-16 | 2010-04-16 | Фармацевтические композиции |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014121260A true RU2014121260A (ru) | 2015-12-10 |
Family
ID=42982643
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011146335/15A RU2532330C2 (ru) | 2009-04-16 | 2010-04-16 | Фармацевтические композиции |
| RU2014121260/15A RU2014121260A (ru) | 2009-04-16 | 2014-05-26 | Фармацевтические композиции |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011146335/15A RU2532330C2 (ru) | 2009-04-16 | 2010-04-16 | Фармацевтические композиции |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20120040898A1 (ru) |
| EP (3) | EP2601949B1 (ru) |
| JP (4) | JP5077786B2 (ru) |
| KR (2) | KR20150046382A (ru) |
| CN (7) | CN105343880A (ru) |
| AR (1) | AR076317A1 (ru) |
| AU (1) | AU2010237748B2 (ru) |
| BR (1) | BRPI1012539A2 (ru) |
| CA (1) | CA2755392A1 (ru) |
| CY (2) | CY1114703T1 (ru) |
| DK (2) | DK2601949T3 (ru) |
| ES (2) | ES2431300T3 (ru) |
| HK (6) | HK1217302A1 (ru) |
| HR (2) | HRP20131120T1 (ru) |
| ME (2) | ME01555B (ru) |
| MX (1) | MX2011010901A (ru) |
| MY (3) | MY182720A (ru) |
| NZ (4) | NZ595314A (ru) |
| PH (3) | PH12015500235B1 (ru) |
| PL (2) | PL2601949T3 (ru) |
| PT (2) | PT2419097E (ru) |
| RS (2) | RS53761B1 (ru) |
| RU (2) | RU2532330C2 (ru) |
| SG (6) | SG2014012462A (ru) |
| SI (2) | SI2419097T1 (ru) |
| SM (1) | SMT201500015B (ru) |
| TW (3) | TW201103534A (ru) |
| UA (2) | UA105216C2 (ru) |
| WO (1) | WO2010119990A1 (ru) |
| ZA (1) | ZA201106727B (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| EP2486029B1 (en) | 2009-09-30 | 2015-06-10 | Boehringer Ingelheim International GmbH | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
| UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
| US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TR201101809A1 (tr) * | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
| US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| MX360304B (es) | 2012-05-17 | 2018-10-29 | Vtv Therapeutics Llc | Composiciones de activador de glucocinasa para el tratamiento de la diabetes. |
| SG11201501510SA (en) * | 2012-08-30 | 2015-04-29 | Taisho Pharmaceutical Co Ltd | Combinations of sglt2 inhibitors and antihypertensive drugs |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| TR201901110T4 (tr) | 2013-04-05 | 2019-02-21 | Boehringer Ingelheim Int | Empagliflozinin terapötik kullanımları. |
| SI2986304T1 (sl) | 2013-04-18 | 2022-04-29 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe |
| TW201513857A (zh) * | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | 協同性組成物 |
| EP3263134B1 (en) * | 2015-02-27 | 2021-05-05 | The Asan Foundation | Composition for preventing or treating valve calcification, containing dpp-4 inhibitor |
| CN105963280B (zh) * | 2016-06-30 | 2018-11-06 | 合肥华方医药科技有限公司 | 一种伏格列波糖口腔速溶膜及其制备方法 |
| CN109843279A (zh) | 2016-10-19 | 2019-06-04 | 勃林格殷格翰国际有限公司 | 包含ssao/vap-1抑制剂和sglt2抑制剂的药物组合、其用途 |
| CN110168098A (zh) * | 2016-11-14 | 2019-08-23 | 高雄医学大学 | 一种检测糖代谢异常的方法及其预防及治疗 |
| EP3781166A1 (en) | 2018-04-17 | 2021-02-24 | Boehringer Ingelheim International GmbH | Pharmaceutical composition, methods for treating and uses thereof |
| KR20190137343A (ko) | 2018-06-01 | 2019-12-11 | 김유찬 | 계량 인덕션 |
| JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4432757A1 (de) | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| JP2003520759A (ja) | 1999-08-31 | 2003-07-08 | アンドルックス ファーマスーティカルズ インコーポレーテッド | 単位核を有する徐放性錠剤 |
| WO2002080936A1 (en) * | 2001-04-04 | 2002-10-17 | Ortho Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and ppar modulators |
| AU2002254567B2 (en) * | 2001-04-11 | 2007-10-11 | Bristol-Myers Squibb Company | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method |
| TW200637839A (en) * | 2005-01-07 | 2006-11-01 | Taisho Pharmaceutical Co Ltd | 1-thio-d-glucitol derivatives |
| JP5152519B2 (ja) * | 2006-06-29 | 2013-02-27 | 大正製薬株式会社 | Ｃ−フェニル１−チオグルシト−ル化合物 |
| JP5194588B2 (ja) * | 2006-07-06 | 2013-05-08 | 大正製薬株式会社 | １−チオ−ｄ−グルシトール誘導体を有効成分として含有する糖尿病の予防又は治療剤 |
| US8039441B2 (en) * | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
| BRPI0718596B8 (pt) * | 2006-11-09 | 2021-05-25 | Boehringer Ingelheim Int | composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina |
| AU2007332476A1 (en) * | 2006-12-14 | 2008-06-19 | Taisho Pharmaceutical Co., Ltd. | 1-phenyl 1-thio-D-glucitol derivative |
| CL2008002427A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| CL2008002425A1 (es) | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta. |
-
2010
- 2010-04-16 KR KR1020157009538A patent/KR20150046382A/ko not_active Application Discontinuation
- 2010-04-16 RS RS20150042A patent/RS53761B1/en unknown
- 2010-04-16 SG SG2014012462A patent/SG2014012462A/en unknown
- 2010-04-16 NZ NZ595314A patent/NZ595314A/xx unknown
- 2010-04-16 ES ES10764570T patent/ES2431300T3/es active Active
- 2010-04-16 MY MYPI2015001283A patent/MY182720A/en unknown
- 2010-04-16 US US13/264,687 patent/US20120040898A1/en not_active Abandoned
- 2010-04-16 ES ES13157571.4T patent/ES2523408T3/es active Active
- 2010-04-16 CN CN201510876739.3A patent/CN105343880A/zh active Pending
- 2010-04-16 AU AU2010237748A patent/AU2010237748B2/en not_active Ceased
- 2010-04-16 CN CN201510876678.0A patent/CN105477639A/zh active Pending
- 2010-04-16 PT PT107645707T patent/PT2419097E/pt unknown
- 2010-04-16 TW TW099111992A patent/TW201103534A/zh unknown
- 2010-04-16 NZ NZ623838A patent/NZ623838A/en not_active IP Right Cessation
- 2010-04-16 PT PT131575714T patent/PT2601949E/pt unknown
- 2010-04-16 SG SG2014014807A patent/SG2014014807A/en unknown
- 2010-04-16 ME MEP-2013-137A patent/ME01555B/me unknown
- 2010-04-16 WO PCT/JP2010/057196 patent/WO2010119990A1/en active Application Filing
- 2010-04-16 SI SI201030365T patent/SI2419097T1/sl unknown
- 2010-04-16 CN CN201510876712.4A patent/CN105343871A/zh active Pending
- 2010-04-16 CN CN201510876636.7A patent/CN105343059A/zh active Pending
- 2010-04-16 DK DK13157571.4T patent/DK2601949T3/da active
- 2010-04-16 DK DK10764570.7T patent/DK2419097T3/da active
- 2010-04-16 BR BRPI1012539A patent/BRPI1012539A2/pt not_active IP Right Cessation
- 2010-04-16 SG SG2014015093A patent/SG2014015093A/en unknown
- 2010-04-16 MX MX2011010901A patent/MX2011010901A/es active IP Right Grant
- 2010-04-16 TW TW105105937A patent/TW201622720A/zh unknown
- 2010-04-16 AR ARP100101273A patent/AR076317A1/es unknown
- 2010-04-16 CN CN2010800169522A patent/CN102395364A/zh active Pending
- 2010-04-16 CA CA2755392A patent/CA2755392A1/en not_active Abandoned
- 2010-04-16 SG SG2014012405A patent/SG2014012405A/en unknown
- 2010-04-16 MY MYPI2011004937A patent/MY156679A/en unknown
- 2010-04-16 EP EP13157571.4A patent/EP2601949B1/en active Active
- 2010-04-16 ME MEP-2015-6A patent/ME02015B/me unknown
- 2010-04-16 RU RU2011146335/15A patent/RU2532330C2/ru not_active IP Right Cessation
- 2010-04-16 UA UAA201113444A patent/UA105216C2/ru unknown
- 2010-04-16 NZ NZ606888A patent/NZ606888A/en not_active IP Right Cessation
- 2010-04-16 KR KR1020117023612A patent/KR20120016051A/ko not_active Application Discontinuation
- 2010-04-16 EP EP14183168.5A patent/EP2829271A3/en not_active Withdrawn
- 2010-04-16 MY MYPI2015001281A patent/MY183793A/en unknown
- 2010-04-16 PL PL13157571T patent/PL2601949T3/pl unknown
- 2010-04-16 CN CN201510876708.8A patent/CN105343060A/zh active Pending
- 2010-04-16 SG SG2011073848A patent/SG175154A1/en unknown
- 2010-04-16 PL PL10764570T patent/PL2419097T3/pl unknown
- 2010-04-16 JP JP2011540651A patent/JP5077786B2/ja active Active
- 2010-04-16 SI SI201030784T patent/SI2601949T1/sl unknown
- 2010-04-16 UA UAA201314870A patent/UA111742C2/uk unknown
- 2010-04-16 CN CN201510876753.3A patent/CN105434430A/zh active Pending
- 2010-04-16 TW TW103133246A patent/TW201500043A/zh unknown
- 2010-04-16 NZ NZ710575A patent/NZ710575A/en not_active IP Right Cessation
- 2010-04-16 RS RS20130508A patent/RS53056B/en unknown
- 2010-04-16 EP EP10764570.7A patent/EP2419097B1/en active Active
- 2010-04-16 SG SG2014012553A patent/SG2014012553A/en unknown
-
2011
- 2011-09-14 ZA ZA2011/06727A patent/ZA201106727B/en unknown
-
2012
- 2012-08-31 JP JP2012191753A patent/JP5660094B2/ja not_active Expired - Fee Related
-
2013
- 2013-11-25 HR HRP20131120AT patent/HRP20131120T1/hr unknown
- 2013-12-05 CY CY20131101103T patent/CY1114703T1/el unknown
-
2014
- 2014-05-26 RU RU2014121260/15A patent/RU2014121260A/ru not_active Application Discontinuation
- 2014-11-05 HR HRP20141080AT patent/HRP20141080T1/hr unknown
- 2014-12-03 JP JP2014245257A patent/JP5910711B2/ja active Active
-
2015
- 2015-01-16 CY CY20151100045T patent/CY1115907T1/el unknown
- 2015-01-19 SM SM201500015T patent/SMT201500015B/xx unknown
- 2015-02-03 PH PH12015500235A patent/PH12015500235B1/en unknown
- 2015-12-25 JP JP2015253932A patent/JP6066144B2/ja active Active
-
2016
- 2016-05-11 HK HK16105353.2A patent/HK1217302A1/zh unknown
- 2016-05-11 HK HK16105348.0A patent/HK1217301A1/zh unknown
- 2016-05-12 HK HK16105415.8A patent/HK1217434A1/zh unknown
- 2016-05-12 HK HK16105417.6A patent/HK1217435A1/zh unknown
- 2016-06-16 HK HK16106920.4A patent/HK1218871A1/zh unknown
- 2016-06-17 HK HK16106970.3A patent/HK1218881A1/zh unknown
-
2019
- 2019-04-30 PH PH12019500959A patent/PH12019500959B1/en unknown
- 2019-04-30 PH PH12019500961A patent/PH12019500961B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014121260A (ru) | Фармацевтические композиции | |
| Liu et al. | Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years | |
| CA2724133C (en) | Medicine consisting of concomitant use or combination of dpp-iv inhibitor and other diabetic medicine | |
| HRP20200828T1 (hr) | Farmaceutski pripravak koji sadrži sglt2-inhibitor, dpp-iv-inhibitor i prema potrebi jedno dodatno antidijabetičko sredstvo, te njegove uporabe | |
| ES2760917T3 (es) | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina | |
| JP2013006854A5 (ru) | ||
| HRP20090446T1 (hr) | Kombinacijska terapija za liječenje dijabetesa i stanja povezanih s njim, te za liječenje stanja koja se poboljšavaju povećanjem nivoa glp-1 u krvi | |
| ES2549955T3 (es) | Prevención de hipoglucemia en pacientes con diabetes mellitus de tipo 2 | |
| AR081254A1 (es) | Composicion farmaceutica que comprende ave0010 e insulina glargina | |
| RU2008115114A (ru) | Применение ингибитора dpp-iv для снижения приступов гликемии | |
| NZ593754A (en) | Dpp-iv inhibitors for treatment of diabetes in paediatric patients | |
| CO6361944A2 (es) | Combinacion de una insulina y un agonista de glp-1 | |
| KR20210024583A (ko) | 요법을 위한 gip/glp1 공효능제 사용 방법 | |
| JP2017515908A5 (ru) | ||
| JP2018509419A5 (ru) | ||
| Lovshin et al. | GLP-1R agonists and endothelial dysfunction: more than just glucose lowering? | |
| RU2020140694A (ru) | Способ лечения гипергликемии | |
| JP2020536121A5 (ru) | ||
| Bryan | From snake venom to ACE inhibitor--The discovery and rise of captopril | |
| NZ602583A (en) | Methods of using diacerein as an adjunctive therapy for diabetes | |
| Davis | Oral hypoglycaemic drugs for the treatment of type 2 diabetes mellitus | |
| Davoren | Glucose-lowering medicines for type 2 diabetes | |
| RU2014150946A (ru) | Способ снижения веса | |
| JP2009501707A5 (ru) | ||
| MX2011004559A (es) | Agente antidiabetico. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20170529 |